Patients with CKD have an altered risk-to-benefit ratio for antithrombotic therapies and are less likely to receive medications of proven benefit, contributing to poorer prognosis.
C hronic kidney disease (CKD) is a pandemic public health problem, with 500 million people worldwide estimated to have some form of kidney injury. Overlapping conditions such as acute kidney injury play an important role in the growing epidemiology of CKD, and underlying CKD is in turn an important risk factor for acute kidney injury and end-stage renal disease. Key factors contributing to the increased prevalence of CKD include the aging population and the growing burden of diabetes mellitus. The prevalence of stage 3 or 4 CKD has been reported to be 38% for adults 70 years old versus 1% in adults 20 to 39 years of age. atients with diabetes mellitus are found to present with CKD in about one third of cases, with diabetic nephropathy as the most common cause of renal impairment. ] However, the risk-tobenefit ratio with antithrombotic therapies may be altered in CKD. 2] Moreover, patients with severe CKD are less likely to receive medications of proven benefit. verall, these findings contribute to explain why patients with reduced renal function have poorer prognosis compared with patients with preserved renal function.
Capodanno et al. (Tue,) studied this question.